BioLegend 通过为生物医学研究提供世界一流的尖端抗体和试剂，使生命科学从研究到治疗的发现成为可能，这些抗体和试剂是在加州圣地亚哥的最先进的工厂中制造的。其使命是通过提供最优质的产品，以及卓越的客户服务和技术支持，加快研究和发现。其产品专业知识涵盖多种研究领域，包括免疫学、神经科学、癌症、干细胞和临床产品。BioLegend 的试剂由卓越的客户服务和质量管理系统提供支持，该系统经过 ISO 13485：2016 认证。BioLegend 对科学界有着坚定的承诺，它突破了科学创新的界限，改变了我们收集和解释科学知识的方式。要了解更多信息，请访问 www.biolegend.com。
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
Transformativedeal significantly scales leading position in life science to acceleratelegendary discoveries in precision medicine
July 26, 2021 06:30 AM Eastern DaylightTime
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer,Inc. (NYSE: PKI) (“PerkinElmer”) today announced it hasentered into an agreement to acquire BioLegend,a leading, globalprovider of life science antibodies and reagents, for approximately $5.25billion in a combination of cash and stock, subject to certain adjustments.
BioLegend provides its academic andbiopharmaceutical customers with best-in-class antibodies and reagents inhigh-growth areas such as cytometry, proteogenomics, multiplex assays,recombinant proteins, magnetic cell separation and bioprocessing. Thetransaction will be the largest in PerkinElmer’s history and is expected toclose by the end of the 2021 calendar year, subject to regulatory approvals andother customary closing conditions.
Privately-held BioLegend has more than700 employees based primarily in the U.S., with estimated 2022 revenues of $380million. Upon joining PerkinElmer, BioLegend will expand PerkinElmer’s existinglife science franchise into new segments, and its state-of-the-art campus inSan Diego, California will become PerkinElmer’s global Center of Excellence(CoE) for research reagent content development for the combined company.
Commenting on the agreement to acquireBioLegend, Prahlad Singh, president and chief executive officer of PerkinElmer,said: “We are thrilled to have the opportunity to bring our technologies andinnovative cultures together to create seamless solutions to push science anddiscovery forward. We believe joining our teams presents an incredibleopportunity to accelerate discoveries that help life science researchersleverage ever-developing technologies and novel approaches to better understandand fight disease.”
Gene Lay, founder, president and chiefexecutive officer of BioLegend, added,“We are very excited to join thePerkinElmer family. The combination will afford us the opportunity to continueto build on our two-decade foundation of innovative science and scale in newand highly attractive PerkinElmer areas such as clinical diagnostics and foodsafety testing. The BioLegend team is eager to enter this new chapter withPerkinElmer, furthering our mission of enabling legendary discovery fromresearch to cure.”
Strategic Alignment of Deal StructureExpected to Lead to Faster Growth and Elevated Margins
PerkinElmer has fully committed bridge financingfrom Goldman Sachs Bank USA in place for the cash portion of the agreed uponpurchase price. The combination is expected to be accretive to PerkinElmer’sexisting revenue growth and margin profile and provide an estimated $0.30 ofadjusted earnings per share accretion in the first full year following closeand greater than $0.50 in the second year following close. The combined companywill generate immediate revenue synergies which are expected to reach $100million annually by the fifth year following the transaction close and nosignificant cost synergies are planned.
PerkinElmer enables scientists,researchers, and clinicians to address their most critical challenges acrossscience and healthcare. With a mission focused on innovating for a healthierworld, we deliver unique solutions to serve the diagnostics, life science,food, and applied markets. We strategically partner with customers to enableearlier and more accurate insights supported by deep market knowledge and technicalexpertise. Our dedicated team of about 14,000 employees worldwide is passionateabout helping customers work to create healthier families, improve the qualityof life, and sustain the well-being and longevity of people globally. TheCompany reported revenue of approximately $3.8 billion in 2020, servescustomers in 190 countries, and is a component of the S&P 500 index.Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
BioLegend enables life science discoveryfrom research to cure by providing world-class, cutting-edge antibodies andreagents for biomedical research, manufactured in its state-of-the-art facilityin San Diego, CA. Its mission is to accelerate research and discovery byproviding the highest quality products at an outstanding value, along withsuperior customer service and technical support. Its product expertise covers adiverse set of research areas including Immunology, Neuroscience, Cancer, Stemcells, and Clinical Products. BioLegend’s reagents are supported by superiorcustomer service and a quality management system that is certified for ISO13485:2016. With a strong commitment to the scientific community, BioLegendpushes the boundaries of scientific innovation, and transforms the way wecollect and interpret scientific knowledge. To learn more, visit www.biolegend.com.